Clinical Trial Update: Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of self-administered pegvaliase (>40 mg/day) in adults with phenylketonuria (PKU) has completed with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Phenylketonuria

Drugs mentioned

• Pegvaliase (pegvaliase)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Phenylketonuria (PKU) | Phase 3 | Status: COMPLETED | Results posted: 2022-02-17